Stock comparison
AbbVie Inc. is 231.9x more valuable than Zymeworks Inc. by market capitalization ($438.31 B vs $1.89 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ABBV is larger
AbbVie Inc. is 231.9x more valuable than Zymeworks Inc. by market capitalization ($438.31 B vs $1.89 B).
Market value leader
ABBV
AbbVie Inc. is 231.9x more valuable than Zymeworks Inc. by market capitalization ($438.31 B vs $1.89 B).
Revenue leader
ABBV
ZYME: $105.97M vs ABBV: $61.16B.
Profit leader
ABBV
ZYME: -$81.13M vs ABBV: $4.23B.
Margin leader
ABBV
ZYME: -76.6% vs ABBV: 6.9% net margin.
| Metric | ZYME | ABBV |
|---|---|---|
| Market cap | $1.89 B | $438.31 B |
| US-listed rank | #2186 | #26 |
| Revenue (latest FY) | $105.97M | $61.16B |
| Net income (latest FY) | -$81.13M | $4.23B |
| Net margin | -76.6% | 6.9% |
| P/E (trailing FY) | - | 103.7x |
| SEC filings | 323 | 1,008 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
AbbVie Inc. is 231.9x more valuable than Zymeworks Inc. by market capitalization ($438.31 B vs $1.89 B).
In their latest fiscal years, Zymeworks Inc. reported $105.97M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Zymeworks Inc. and AbbVie Inc., or browse the full rankings.